Composition for inducing immune tolerance
The use of pluripotent stem cells to form teratomas that express CD24 and produce erythropoietin, accumulating regulatory T cells, addresses the challenges of transplant rejection by inducing immune tolerance in allogeneic transplants, enhancing engraftment and reducing immunosuppressive drug reliance and associated complications.
Patent Information
- Application Number
- PCT/JP2024/016734
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-30
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-07
AI Technical Summary
Current methods for controlling rejection in allogeneic transplants, such as those using immunosuppressive drugs, come with significant side effects and complications, necessitating a new approach to induce immune tolerance without relying on suppressive agents or reducing their use.
A composition comprising pluripotent stem cells capable of forming teratomas or teratomas derived from these cells, which express CD24 and have the ability to produce erythropoietin and accumulate regulatory T cells, is used to induce immune tolerance in recipients, potentially eliminating the need for immunosuppressive drugs.
This approach effectively induces immune tolerance in allogeneic transplants by promoting the engraftment of donor-derived cells, tissues, or organs without the adverse effects associated with traditional immunosuppressive therapies, improving transplant success rates and reducing complications.
Smart Images

Figure JP2024016734_07112024_PF_FP_ABST
Abstract
Description
Composition for inducing immune tolerance
[0001] The present invention relates to a composition for inducing immune tolerance and its use.
[0002] In allogeneic transplantation, the control of rejection caused by the recipient's immune system recognizing the donor-derived transplant as a foreign body is an important issue that determines the success of the treatment. Even in transplantation medicine using pluripotent stem cells such as induced pluripotent stem cells (iPS cells) and embryonic stem cells (ES cells), when pluripotent stem cells or cells derived from pluripotent stem cells are transplanted into allogeneic recipients, it has been reported that immunological rejection occurs not only in recipients with completely mismatched major histocompatibility complex (MHC) haplotypes, but also in recipients with completely matched MHC haplotypes (e.g., Non-Patent Documents 1 to 3).
[0003] The main approach to controlling rejection is to suppress the recipient's immune response by administering drugs such as cyclosporine and tacrolimus. However, immunosuppressants can cause infections and malignant tumors due to immunosuppression, and long-term use can also cause complications such as nephrotoxicity, hypertension, hyperlipidemia, and diabetes. Therefore, new methods of rejection control that do not rely on immunosuppressants or that require reduced amounts of immunosuppressants are needed.
[0004] Immune tolerance induction has attracted attention as a means of controlling the rejection reaction of recipients in allogeneic transplants, and it has been reported that, for example, an immunomodulator for immune tolerance induction containing regulatory T cells (also called Tregs) as an active ingredient (Patent Document 1), an immune tolerance inducer containing hematopoietic stem cells, hematopoietic progenitor cells, or a mixture thereof as a tolerogen active ingredient (Patent Document 2), and that administration of donor-derived B cells or dendritic cells to recipients before transplantation improves the tissue retention rate in allogeneic transplants (Non-Patent Documents 4 and 5), etc. Furthermore, an approach has been reported in which cells with immunoregulatory ability differentiated from pluripotent stem cells are used to induce immune tolerance (Non-Patent Document 6).
[0005] WO2006 / 107101 Japanese Patent Application Publication No. 11-180892
[0006] Mizukami Y et al., PLOS One, 2014, 9(6): e98319.Kawamura A. et al., Scientific Reports, 2016, 6:19464.Ishigaki H et al., Cell Transplant., 2021, 30: 0963689721992066.Gao J. et al., PLOS One, 2013, 8 (10): e77761.Yamano T. et al., blood, 2011, 117 (9): 2640-2648.Sasaki H. et al, Transplantation, 2015, 99(11): 2301-2310.
[0007] The present inventors have found that in allogeneic recipients with MHC compatibility between the transplanted pluripotent stem cells and the pluripotent stem cells, the transplanted pluripotent stem cells are not rejected and form teratomas without the use of immunosuppressants, and that immune tolerance is induced by the transplantation of pluripotent stem cells.
[0008] The present disclosure provides the following inventions: Item 1. A composition for inducing immune tolerance, comprising pluripotent stem cells capable of teratoma formation, or teratomas derived from the pluripotent stem cells. Item 2. The composition according to Item 1, wherein the pluripotent stem cells express CD24. Item 3. The composition according to Item 1 or 2, wherein the teratomas express CD24. Item 4. The composition according to any one of Item 1 to 3, wherein the teratomas have the ability to produce erythropoietin. Item 5. The composition according to any one of Item 1 to 4, wherein the teratomas have the ability to accumulate or infiltrate regulatory T cells. Item 6. The composition according to any one of Item 1 to 5, wherein the pluripotent stem cells are embryonic stem cells or induced pluripotent stem cells. Item 7. The composition according to any one of Item 1 to 6, for use in a mammalian individual that is MHC-compatible with the pluripotent stem cells. Item 8. The composition according to any one of Item 1 to 7, for use in a recipient of a transplant of donor-derived cells, tissue, or organs. Item 9. The composition according to Item 8, wherein the pluripotent stem cells are derived from a donor. Item 10. The composition according to Item 8 or 9, wherein the recipient is MHC-compatible with the donor. Item 10A. The composition according to any one of Items 1 to 7, for use in a mammalian individual with an autoimmune disease. Item 11. A method for inducing immune tolerance in a mammalian individual, comprising administering to a mammalian individual in whom immune tolerance is desired an effective amount of pluripotent stem cells capable of teratoma formation, or a teratoma derived from said pluripotent stem cells. Item 11A. The method according to Item 11, wherein the pluripotent stem cells express CD24. Item 11B. The method according to Item 11 or 11A, wherein the teratoma expresses CD24. Item 11C. The method according to Item 11, 11A, or 11B, wherein the teratoma has the ability to produce erythropoietin. Item 11D. Item 11. The method of any one of Items 11, 11A to 11C, wherein the teratoma has the ability to accumulate or infiltrate regulatory T cells. Item 11E. The method of any one of Items 11, 11A to 11D, wherein the pluripotent stem cells are embryonic stem cells or induced pluripotent stem cells. Item 11F. The method of any one of Items 11, 11A to 11E, for use in a mammalian individual that is MHC-compatible with the pluripotent stem cells.Item 11G. The method of any one of Items 11, 11A to 11F, for use in a recipient receiving a transplant of donor-derived cells, tissues or organs. Item 11H. The method of Item 11G, wherein the pluripotent stem cells are derived from a donor. Item 11I. The method of Item 11G or 11H, wherein the recipient is MHC-compatible with the donor. Item 12. A method for improving the engraftment rate of donor-derived cells, tissues or organs in a recipient, comprising administering to the recipient an effective amount of pluripotent stem cells capable of teratoma formation, or a teratoma derived from said pluripotent stem cells, and transplanting the donor-derived cells, tissues or organs into the recipient. Item 12A. The method of Item 12, wherein the pluripotent stem cells express CD24. Item 12B. The method of Item 12 or 12A, wherein the teratoma expresses CD24. Item 12C. Item 12. The method of Item 12, 12A, or 12B, wherein the teratoma has the ability to produce erythropoietin. Item 12D. The method of any one of Items 12, 12A to 12C, wherein the teratoma has the ability to accumulate or infiltrate regulatory T cells. Item 12E. The method of any one of Items 12, 12A to 12D, wherein the pluripotent stem cells are embryonic stem cells or induced pluripotent stem cells. Item 12F. The method of any one of Items 12, 12A to 12E, wherein the recipient is MHC-compatible with the pluripotent stem cells. Item 12G. The method of any one of Items 12, 12A to 12F, wherein the pluripotent stem cells are derived from a donor. Item 12H. The method of any one of Items 12, 12A to 12G, wherein the recipient is MHC-compatible with the donor. Item 12I. Item 12. The method of any one of Items 12 and 12A to 12H, wherein the administration of pluripotent stem cells or teratomas and the transplantation of donor-derived cells, tissues or organs are performed simultaneously or with an interval of one day or less. Item 12J. The method of any one of Items 12 and 12A to 12H, wherein the administration of pluripotent stem cells or teratomas is followed by the transplantation of donor-derived cells, tissues or organs with an interval of more than one day. Item 13. A method for treating an autoimmune disease, comprising administering an effective amount of pluripotent stem cells capable of teratoma formation, or a teratoma derived from said pluripotent stem cells, to a mammalian individual having the autoimmune disease. Item 13A. The method of Items 13, wherein the pluripotent stem cells express CD24.Item 13B. The method of Item 13 or 13A, wherein the teratoma expresses CD24. Item 13C. The method of Item 13, 13A, or 13B, wherein the teratoma has the ability to produce erythropoietin. Item 13D. The method of any one of Items 13, 13A to 13C, wherein the teratoma has the ability to accumulate or infiltrate regulatory T cells. Item 13E. The method of any one of Items 13, 13A to 13D, wherein the pluripotent stem cells are embryonic stem cells or induced pluripotent stem cells. Item 13F. The method of any one of Items 13, 13A to 13E, wherein a mammalian individual with an autoimmune disease is MHC-compatible with the pluripotent stem cells. Item 14. A medical transplant kit comprising an effective amount of pluripotent stem cells capable of teratoma formation or teratomas derived from the pluripotent stem cells, and donor-derived cells, tissues, or organs.
[0009] According to the present invention, immune tolerance can be induced in a mammalian individual in which induction of immune tolerance is desired.
[0010] This graph shows the luciferase luminescence intensity at the inoculation site of recipient mice (CBA / N, B6C3F1, BALB / c) subcutaneously inoculated with luciferase-expressing CBA / N mouse-derived iPS cells (Luc-CBA-iPS). The graph shows the mean ± standard error. This graph also shows the appearance and histological staining images of tumors formed at the transplantation site of a recipient mouse (B6C3F1) subcutaneously inoculated with CBA / N mouse-derived iPS cells (CBA-iPS). This graph also shows the engraftment period of donor mouse (B6C3F1, CBA / N, BALB / c) skin fragments transplanted into recipient mice (B6C3F1) subcutaneously inoculated with CBA-iPS. The horizontal axis of the graph represents the time from the date of skin grafting to the date of rejection (this also applies to all graphs showing the engraftment period of skin fragments). This graph shows the engraftment period of donor mouse (B6C3F1, BALB / c, 129X1, CBA / N) skin fragments transplanted onto recipient mice (B6C3F1) subcutaneously inoculated with CBA / N mouse-derived ES cells (CBA-ES). This graph also shows the engraftment period of donor mouse (B6C3F1, BALB / c, CBA / N) skin fragments transplanted onto recipient mice (B6C3F1). Figure 5A shows the results of untreated recipient mice, while Figures B and C show the results of recipient mice subcutaneously inoculated with CBA-iPS cells on the same day and 10 days before skin grafting, respectively. This graph also shows the engraftment period of donor mouse (B6C3F1, BALB / c, CBA / N) skin fragments transplanted onto recipient mice (B6C3F1). Figure 6A to C show the results of recipient mice subcutaneously inoculated with CBA-iPS cells 20, 30, and 40 days before skin grafting, respectively. Figure 7 shows the engraftment period of skin fragments from donor mice (B6C3F1, BALB / c, CBA / N) transplanted onto recipient mice (B6C3F1). Figure 7A shows the results for recipient mice inoculated subcutaneously with CBA-iPS cells 40 days before skin transplantation, and the teratomas formed 20 days before skin transplantation were excised. Figure 7B shows the results for recipient mice inoculated subcutaneously with CBA-iPS cells 40 days before skin transplantation, and the teratomas formed 20 days after skin transplantation were excised. Images of luciferase activity in teratomas, spleens, teratoma-draining lymph nodes, and teratoma-distal lymph nodes were taken from B6C3F1 mice subcutaneously inoculated with Luc-CBA-iPS cells.These dot plots show the results of flow cytometry analysis of CBA-iPS cells (Figure 9, right) and teratoma cell populations formed in B6C3F1 mice subcutaneously inoculated with CBA-iPS cells (Figure 9, left). The numbers in the upper right corner of each plot indicate the percentage of CD24-positive cells (the percentage of cells within the square in the CD45-negative live cell population). These graphs show the duration of engraftment of skin fragments from donor mice (BALB / c, CBA / N, B6C3F1) transplanted onto recipient mice (B6C3F1). Figure 10A shows the results for untreated recipient mice, Figure 10B shows the results for recipient mice subcutaneously inoculated with CBA-iPS cells prior to skin grafting, and Figure 10C shows the results for recipient mice subcutaneously inoculated with Cd24a-knockout CBA-iPS cells prior to skin grafting. 14A and 14B show graphs showing erythropoietin gene expression levels in CBA-iPS cells, B6C3F1 mouse ovaries, and teratomas formed in B6C3F1 mice subcutaneously inoculated with CBA-iPS cells (20 and 40 days after subcutaneous inoculation). The graphs show mean ± standard error. The upper row shows immunohistochemical staining images using an anti-erythropoietin antibody and the lower row shows light microscopic images of B6C3F1 mouse kidneys and teratomas formed in B6C3F1 mice subcutaneously inoculated with CBA-iPS cells (20 and 40 days after subcutaneous inoculation). The graphs show the engraftment period of a skin fragment from a donor mouse (CBA / N) transplanted into a recipient mouse (B6C3F1) under erythropoietin administration. The graphs show the blood anti-dsDNA IgG concentration (FIG. 14A) and lymph node weight (FIG. 14B) of C3H / lpr mice subcutaneously inoculated with CBA-iPS cells. Plots show the actual measured values for each individual, and graphs show the mean ± standard error. Statistical analysis was performed using Tukey's HSD test. *p<0.05, **p<0.01. Figure 15 shows the results of single-cell RNA analysis of regulatory T cells (Tregs) infiltrating teratomas formed in B6C3F1 mice subcutaneously inoculated with CBA-iPS cells. Figure 15A shows a plot of Tregs clustered based on gene expression information. Figure 15B is a heat map showing the marker genes for each Treg cluster. Figure 15C shows the gene expression of immunosuppressive factors (Il10, Il2ra, Clta4, Entpd1, and Nt5e) in Tregs.Figure 15D is a bar graph showing the abundance ratio of each Treg cluster in teratomas over time. Figure 15E is a graph showing the engraftment period of donor mouse (CBA / N) skin fragments transplanted onto recipient mice (B6C3F1) under administration of anti-CD25 antibody or control IgG. Figure 15F is a graph showing the engraftment period of donor mouse (CBA / N) skin fragments transplanted onto recipient mice (B6C3F1). In all trials shown in Figure 17, subcutaneous inoculation of CBA-iPS cells and skin transplantation were performed on the same day.
[0011] The following description may be based on representative embodiments or specific examples, but the present invention is not limited to such embodiments or specific examples. The upper and lower limit values of each numerical range shown in this specification can be combined arbitrarily. Furthermore, in this specification, numerical ranges expressed using "to" or "-" mean ranges that include the numerical values at both ends as upper and lower limits, unless otherwise specified.
[0012] The present disclosure provides a composition for inducing immune tolerance, which contains pluripotent stem cells capable of forming teratoma or a teratoma derived from the pluripotent stem cells. The present disclosure also provides an immune tolerance inducer, which contains pluripotent stem cells capable of forming teratoma or a teratoma derived from the pluripotent stem cells.
[0013] In the present disclosure, pluripotent stem cells refer to cells that have the ability to self-renew and pluripotency, which is the ability to differentiate into all cell lineages belonging to the three germ layers (ectoderm, mesoderm, and endoderm). Examples of pluripotent stem cells include iPS cells, ES cells, and embryonic germ stem cells (EG cells). The pluripotent stem cells used in the present disclosure are preferably iPS cells or ES cells, and more preferably iPS cells.
[0014] The pluripotent stem cells used in the present disclosure are mammalian pluripotent stem cells, and are preferably pluripotent stem cells derived from a mammalian individual of the same species as the individual in whom induction of immune tolerance is desired.
[0015] Mammals in the present disclosure include humans and non-human mammals, and examples of non-human mammals include rodents including mice, rats, hamsters, and guinea pigs, primates including monkeys and chimpanzees, livestock including pigs, cows, goats, horses, and sheep, and pets including dogs and cats. Preferred mammals are mice or humans, and more preferably humans.
[0016] iPS cells can be generated by reprogramming methods known to those skilled in the art. One example of a reprogramming method involves introducing genes known as reprogramming factors or the proteins encoded thereby, such as the four genes Oct 3 / 4, Sox 2, Klf 4, and Myc (c-Myc, N-Myc, and L-Myc), into somatic cells, such as fibroblasts or blood cells (e.g., peripheral blood-derived mononuclear cells), and culturing the cells under appropriate conditions to induce pluripotent cells. Other examples of reprogramming methods include substituting drugs such as low-molecular-weight compounds for the genes (e.g., Hou P. et al., 2013, Science, 9; 341(6146), 651-4) or using microRNAs (Miyoshi N. et al., Cell Stem Cell, 2011, 8, 633-638).
[0017] ES cells can be prepared, for example, by culturing the inner cell mass present in a pre-implantation blastocyst-stage embryo on feeder cells or in a medium containing LIF or FGF 2. Human embryonic stem cells include those established from human embryos within 14 days of fertilization.
[0018] In the present disclosure, pluripotent stem cells provided by cell banks or commercially available pluripotent stem cells can also be used. For example, human induced pluripotent stem cell lines such as 201B7 cells, 201B7-Ff cells, 253G1 cells, 253G4 cells, 1201C1 cells, 1205D1 cells, 1210B2 cells, and 1231A3 cells established at Kyoto University are available from Kyoto University and iPS Academia Japan, Inc.
[0019] Pluripotent stem cells can be produced, maintained, and expanded in the presence of feeder cells. Feeder cells are cells other than pluripotent stem cells that are used to maintain the undifferentiated state of pluripotent stem cells, and examples of such cells include mouse fibroblasts (MEF), human fibroblasts, and SNL cells. Feeder cells are preferably subjected to growth-inhibiting treatment, such as a growth inhibitor such as mitomycin C or gamma-ray irradiation, before use.
[0020] Pluripotent stem cells can also be generated, maintained, and expanded in the absence of feeder cells (feeder-free culture). Feeder-free culture refers to conditions in which feeder cells are not added or are substantially absent. Media for feeder-free culture include, for example, Essential 8 medium, Essential 6 medium, TeSR medium, mTeSR medium, mTeSR-E8 medium, Stabilized Essential 8 medium, and StemFit (registered trademark).
[0021] Furthermore, unless otherwise specified, cells in the present disclosure can be cultured using BME medium, BGJb medium, CMRL 1066 medium, Glasgow MEM medium, Improved MEM Zinc Option medium, IMDM medium, Medium 199 medium, Eagle MEM medium, αMEM medium, DMEM medium, F-12 medium, DMEM / F12 medium, IMDM / F12 medium, Ham's medium, RPMI 1640 medium, Fischer's medium, or a mixture thereof.
[0022] The pluripotent stem cells used in the present disclosure maintain an undifferentiated state and have the ability to form teratomas.
[0023] The undifferentiated state of pluripotent stem cells can be confirmed by detecting the expression of undifferentiated markers, such as Oct3 / 4, Nanog, TRA-1-60, SSEA1, SSEA4, TRA-1-81, TRA-2-49, and Rex-1. When the expression of one or more, preferably two or more, and more preferably three or more of these markers is detected, the pluripotent stem cells can be determined to maintain their undifferentiated state.
[0024] In the present disclosure, marker expression can be confirmed by detecting or measuring the expression of a marker gene or marker protein. Gene expression can be detected and measured by common methods such as hybridization, PCR, and RNA-Seq using the nucleotide sequence information of the target gene. Protein expression can be detected and measured by common methods such as ELISA, Western blotting, and flow cytometry using an antibody specific to the target protein.
[0025] The undifferentiated state of pluripotent stem cells can also be confirmed by assessing their ability to differentiate into three germ layers (endoderm, mesoderm, and ectoderm). For example, if embryoid bodies (EBs) formed in vitro from pluripotent stem cells contain endoderm, mesoderm, and ectoderm cells, the pluripotent stem cells can be determined to have the ability to differentiate into the three germ layers and therefore maintain an undifferentiated state. Furthermore, for example, if pluripotent stem cells are seeded in vitro in a medium for endoderm differentiation, a medium for mesoderm differentiation, and a medium for ectoderm differentiation, respectively, and differentiation into endoderm, mesoderm, and ectoderm cells is observed, the pluripotent stem cells can be determined to have the ability to differentiate into the three germ layers and therefore maintain an undifferentiated state. The presence of cells of each germ layer can be confirmed by observing cell morphology and detecting ectodermal markers (B-III tubulin, PAX6, MAP2, TUJ1, NESTIN, etc.), mesodermal markers (Brachyury, MSX1, αSMA, NCAM, etc.), and endodermal markers (SOX17, AFP, FOXA2, etc.).
[0026] The teratoma-forming ability of pluripotent stem cells can be confirmed by transplanting the pluripotent stem cells into an immunodeficient animal such as a NOD-Scid mouse or a Scid mouse, or into an animal that is MHC-compatible with the pluripotent stem cells, and evaluating whether the formed tumor contains endoderm, mesoderm, and ectoderm cells. Pluripotent stem cells can be determined to have teratoma-forming ability if they cause tumors containing cells of all three germ layers to form in the transplanted animal.
[0027] The immune tolerance induction composition and immune tolerance inducer may also contain a teratoma formed from pluripotent stem cells that maintain undifferentiated state and have teratoma-forming ability. The contained teratoma may be in the form of a teratoma cell mass formed from the pluripotent stem cells as it is, or in the form of a part of a teratoma cell mass collected from the teratoma cell mass, or in the form of tissue or cells separated from the teratoma cell mass.
[0028] In one embodiment, the pluripotent stem cells express CD24, i.e., are CD24-positive. In one embodiment, the teratoma expresses CD24, i.e., are CD24-positive. The immune tolerance induction composition and immune tolerance inducer may contain a CD24-positive pluripotent stem cell population, and may also contain a CD24-positive teratoma cell population. The CD24-positive cell population contains CD24-positive cells at 70% or more, preferably 80% or more, and more preferably 90% or more of the entire cell population. The proportion of CD24-positive cells in the entire cell population can be determined by analyzing the cell population by flow cytometry.
[0029] CD24, also known as heat-stable antigen (HSA) or nectadrin, is a cell adhesion protein primarily expressed on immune cells, epithelial cells, neurons, and muscle cells. The amino acid sequences of the human CD24 isoform a preproprotein have been registered with the National Center for Biotechnology Information (NCBI) as NP_001278666.1, NP_001278667.1, NP_001346013.1, and NP_037362.1, and the mRNA sequences have been registered as NM_001291737.1, NM_001291738.1, NM_001359084.1, and NM_013230.3. The amino acid sequence of human CD24 isoform b has been registered with NCBI as NP_001278668.1, and the mRNA sequence has been registered as NM_001291739.1. In addition, the amino acid sequence of mouse CD24 (called Cd24a) has been registered in NCBI as NP_033976.1, and the mRNA nucleotide sequence as NM_009846.2 (both searched on April 26, 2023).
[0030] In certain embodiments, the teratoma has the ability to produce erythropoietin. The erythropoietin production ability of a teratoma can be confirmed by detecting or measuring the expression of the erythropoietin gene or protein in the teratoma. If the expression level of the erythropoietin gene or protein in the teratoma is higher than the expression level in negative control cells, tissues, or organs known not to produce erythropoietin, or is comparable to the expression level in positive control cells, tissues, or organs known to produce erythropoietin, such as kidneys and ovaries, the teratoma can be determined to have the ability to produce erythropoietin.
[0031] Erythropoietin is a glycoprotein hormone that regulates red blood cell production and hemoglobin biosynthesis. It is known to induce immune tolerance to allogeneic donor-derived transplants (Purroy C. et al., 2017, J. Am. Soc. Nephrol, 28(8):2377-2392). The amino acid sequence of the human erythropoietin precursor is registered with NCBI as NP_000790.2, and the mRNA sequence is registered as NM_000799.4. The amino acid sequence of the mouse erythropoietin precursor is registered with NCBI as NP_001299804.1 and NP_031968.1, and the mRNA sequence is registered as NM_001312875.1 and NM_007942.2 (both retrieved on April 27, 2023).
[0032] In one embodiment, a teratoma has the ability to accumulate regulatory T cells (a type of CD4-positive helper T cell population with immunosuppressive ability) around the teratoma or to infiltrate the teratoma (also referred to as the "ability to accumulate or infiltrate regulatory T cells"). This ability can be confirmed by administering pluripotent stem cells to an MHC-compatible mammalian individual to form a teratoma, or by transplanting a teratoma into an MHC-compatible mammalian individual and allowing it to engraft, followed by detecting regulatory T cells around or within the teratoma. Known methods for detecting regulatory T cells include, for example, immunohistological staining or flow cytometry analysis using antibodies that bind to known regulatory T cell markers (e.g., CD25), and gene expression analysis of known regulatory T cell markers by RNA-seq or the like.
[0033] Immune tolerance induction compositions and immune tolerance inducers containing pluripotent stem cells can induce immune tolerance with or without teratoma formation in mammalian individuals that have MHC compatibility with the contained pluripotent stem cells. Furthermore, immune tolerance induction compositions and immune tolerance inducers containing teratomas can induce immune tolerance in mammalian individuals that have MHC compatibility with the contained teratomas.
[0034] Immune tolerance refers to a state in which the immune system is unresponsive to antigens that may elicit an immune response. Immune tolerance can be divided into self-tolerance, which is immune unresponsiveness to self-antigens, and acquired tolerance (also called induced tolerance), which is immune unresponsiveness to non-self antigens. Acquired tolerance is known to be induced by administering non-self antigens under certain conditions, and is thought to involve the suppression of immune responses to non-self antigens by regulatory T cells. Furthermore, autoimmune diseases and allergic diseases are thought to be caused by the breakdown of immune tolerance to self and non-self, respectively.
[0035] In the present disclosure, induction of immune tolerance refers to inducing a state of immune unresponsiveness to a specific antigen, and includes, for example, delaying the onset or progression of an immune response, weakening the strength of an immune response, etc. In the present disclosure, immune tolerance may be directed to either a self-antigen or a non-self-antigen.
[0036] The immune tolerance induction composition and immune tolerance inducer of the present disclosure are used in mammals in which induction of immune tolerance is desired. The immune tolerance induction composition and immune tolerance inducer can be used, for example, to induce immune tolerance to donor-derived grafts, which are non-self antigens, in mammals that will become recipients of cell, tissue, or organ transplants, and can also be used, for example, to control, and preferably suppress, immune responses to self antigens in mammals with autoimmune diseases. The mammals in which the immune tolerance induction composition and immune tolerance inducer are used preferably have MHC compatibility with the pluripotent stem cells contained in the immune tolerance induction composition and immune tolerance inducer, or with the pluripotent stem cells from which teratomas are derived contained therein.
[0037] In the present disclosure, "MHC compatible" means that the donor mammalian individual and the donor-derived transplant do not have different alleles at some or all of the major MHC loci from the recipient mammalian individual. For example, when pluripotent stem cells do not have different alleles at some or all of the major MHC loci from the mammalian individual (recipient) in which the immune tolerance induction composition and immune tolerance inducer are used, the mammalian individual is MHC compatible with the pluripotent stem cells.
[0038] Furthermore, for example, when both MHC haplotypes of the pluripotent stem cells are included in the MHC haplotypes of the mammalian individual (recipient), i.e., when the pluripotent stem cells are MHC homozygous and the recipient has the same MHC haplotype as the pluripotent stem cells, or when the MHC duplotype of the pluripotent stem cells is identical to the MHC duplotype of the recipient, the mammalian individual is MHC compatible with the pluripotent stem cells.
[0039] In the present disclosure, MHC incompatible means that the donor mammalian individual has different alleles at all major MHC loci than the recipient mammalian individual.
[0040] In clinical applications in humans, it is desirable that the donor does not have alleles that differ from the recipient, even in some of the major MHC loci (HLA loci), because rejection reactions that cannot be suppressed by immunosuppressants can lead to severe prognosis.
[0041] MHC compatibility can be conventionally confirmed by histocompatibility tests such as HLA typing and lymphocyte crossmatch, which determine donor-recipient compatibility.
[0042] Major MHC loci in mice include H-2K, H-2D, H-2L, IA, and IE, and may further include any one, preferably all, of Qa-2 and Qa-1. Mouse MHC haplotypes are designated according to specific sets of alleles at the major loci. For example, MHC haplotype b (also called H-2b) is H-2K. b , H-2D b , H-2L null , I.A. b , IE null The haplotype with the allele set is MHC haplotype d (also called H-2d), which is H-2K. d , H-2D d , H-2L d , I.A. d , IE d MHC haplotype k (also called H-2k) is a haplotype with an allele set of k , H-2D k , H-2L null , I.A. k , IE k This corresponds to a haplotype having the allele set:
[0043] Major MHC loci in humans include HLA-A, HLA-B, and HLA-DR, and may further include any one, preferably all, of HLA-C, HLA-DQ, and HLA-DP.
[0044] An example of an MHC-compatible human is a transplant in which a donor with homozygous genotypes at the three loci of HLA-A, HLA-B, and HLA-DR is transplanted to a recipient with a combination of at least one allele at the corresponding loci that matches the allele at the locus, but this is not limited to three loci. Specifically, there is HLA half-identical transplantation, in which cells, tissues, or organs are transplanted from iPS cells generated from cells contained in peripheral blood or umbilical cord blood of a donor with homozygous HLA-A, HLA-B, and HLA-DR of *24:02-*52:01-*15:02, *33:03-*44:03-*13:02, *24:02-*07:02-*01:01, or *24:02-*54:01-*04:05. This is the case when transplanting to a recipient with HLA-DR of *24:02-*52:01-*15:02, *33:03-*44:03-*13:02, *24:02-*07:02-*01:01, or *24:02-*54:01-*04:05. In addition, HLA-A, HLA-B, and HLA-DR with *24:02-*52:01-*15:02, *33:03-*44:03-*13:02, *24:02-*07:02-*01:01, or *24:02-*54:01-*04:05 are known to be frequently occurring HLAs in Japan (see WO2015 / 125941 and the iPS cell stock cells (HLA homozygous donor) Kyoto University iPS Cell Research Foundation (https: / / www.cira-foundation.or.jp / j / research-institution / ips-stock-project / homozygous.html)).
[0045] When the immune tolerance induction composition and immune tolerance inducer are used in a mammalian individual receiving a cell, tissue, or organ transplant, the pluripotent stem cells may be prepared using cells collected from the transplant donor, or may be prepared using cells collected from an individual of the same species as the recipient and transplant donor but different from either of them. In the latter case, it is preferable that the pluripotent stem cells have an MHC haplotype that completely matches that of the transplant donor, or an MHC duplotype that completely matches that of the transplant donor.
[0046] The composition for inducing immune tolerance is not limited as long as it contains pluripotent stem cells or teratomas and a liquid in which they can survive, and may be in the form of, for example, a cell suspension. The liquid in which pluripotent stem cells and teratomas can survive may be any liquid commonly used in cell preparations, such as water, saline, phosphate-buffered saline, cell culture medium, etc. The composition for inducing immune tolerance may also contain cells other than pluripotent stem cells and teratomas, and may also contain pharmaceutically acceptable ingredients such as adjuvants, buffers, antioxidants, preservatives, excipients, carriers, and other active pharmaceutical ingredients. Pharmaceutically acceptable ingredients are well known to those skilled in the art, and those skilled in the art can select and use them as appropriate within the scope of their ordinary skill.
[0047] The immune tolerance induction composition and immune tolerance inducer can be administered to a mammalian individual in whom induction of immune tolerance is desired in an amount effective to induce immune tolerance in the individual, and can be administered one or more times so as to maintain the immune tolerance state for the period for which immune tolerance is desired. In one embodiment, the amount effective to induce immune tolerance means an amount effective to form or engraft a teratoma. In one embodiment, the maintenance of the immune tolerance state can be evaluated using as an indicator whether the formed teratoma is maintained. The immune tolerance induction composition and immune tolerance inducer can be administered, for example, by subcutaneous or intradermal inoculation.
[0048] In a preferred embodiment, the immune tolerance induction composition and immune tolerance inducer are administered to a recipient in allogeneic transplantation to induce immune tolerance to a donor-derived graft in the recipient. The allogeneic transplant is preferably MHC-compatible. In a preferred embodiment, the donor of the allogeneic transplant does not have alleles different from the recipient at all major MHC loci (HLA loci). The immune tolerance induction composition and immune tolerance inducer can induce immune tolerance in a recipient even in a transplant that is MHC-compatible but has a large degree of minor histocompatibility antigen mismatch. Therefore, matching of minor histocompatibility antigens is not required in allogeneic transplantation. The transplant may be any of cells (e.g., but not limited to, retinal pigment epithelium, dopaminergic neural progenitor cells, glial cells, etc.), tissues (e.g., but not limited to, skin, bone, pancreatic islets, heart valves, blood vessels, cornea, retina, etc.), or organs (e.g., but not limited to, heart, kidney, liver, etc.). It is expected that the use of immune tolerance induction compositions and immune tolerance inducers will make it possible to perform allogeneic transplantation under conditions with reduced or no immunosuppressants compared to conventional methods.
[0049] In a preferred embodiment, the immune tolerance-inducing composition and immune tolerance-inducing agent are administered to a patient with an autoimmune disease to induce immune tolerance to a self-antigen. In a preferred embodiment, the immune tolerance-inducing composition and immune tolerance-inducing agent can serve as a therapeutic agent for an autoimmune disease. Here, "treatment" includes any medical intervention aimed at delaying or halting the progression of an autoimmune disease, regressing or eliminating lesions, or alleviating or curing symptoms.
[0050] Examples of autoimmune diseases include lymphoproliferative diseases, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, polymyositis, dermatomyositis, scleroderma, hyperthyroidism, hypothyroidism, autoimmune adrenal insufficiency, true red blood cell anemia, multiple sclerosis, autoimmune hepatitis, and type 1 diabetes.
[0051] The immune tolerance-inducing composition and immune tolerance-inducing agent can be used in combination with treatments to suppress the immune system, examples of which include administration of immunosuppressants, radiation exposure, T cell depletion treatment, etc.
[0052] Examples of immunosuppressants include cyclosporine, tacrolimus, mycophenolate mofetil, steroids (e.g., methylprednisolone), and T cell activation inhibitors. Examples of T cell activation inhibitors include drugs that inhibit the binding of the costimulatory molecule CD28 on T cells to CD80 / CD86 on antigen-presenting cells, such as CTLA-4Ig (e.g., abatacept), a fusion protein of the extracellular portion of CTLA-4 and the Fc portion of IgG; drugs that inhibit the binding of the costimulatory molecule CD40L8 on T cells to CD40 on antigen-presenting cells, such as anti-CD40L (CD154) antibodies; and drugs that inhibit the binding of the IL-2 receptor α chain (CD25) on T cells to IL-2, such as anti-CD25 monoclonal antibodies (e.g., basiliximab). T cell activation inhibitors are also called costimulatory blockades (CBs). To suppress the immune system, one immunosuppressant may be used alone or multiple immunosuppressants may be used in combination.
[0053] The irradiation may be any irradiation typically performed as part of the pretreatment of a recipient prior to transplantation therapy, and is preferably total body irradiation or thymus irradiation. The irradiation dose can be appropriately adjusted, for example, to a single dose of 1 Gy or more for total body irradiation of a human, or 3 Gy or more for thymus irradiation, without reaching a lethal dose.
[0054] The T cell depletion treatment may be any treatment typically performed as one of the pretreatments administered to recipients during transplantation therapy, including administration of anti-T cell antibodies and steroids. Examples of anti-T cell antibodies include anti-CD4 antibodies, anti-CD8 antibodies, anti-CD3 antibodies, anti-TCR antibodies, and anti-thymocyte globulin (ATG), and it is preferable to administer one or more of these in combination to the recipient. In a preferred embodiment, the anti-T cell antibody is a combination of anti-CD4 antibodies and anti-CD8 antibodies, which are preferably administered to the recipient intravenously or intraperitoneally simultaneously or sequentially. The dose may be any amount sufficient to eliminate T cells in the recipient's body.
[0055] In one embodiment, the recipient preferably undergoes radiation or T-cell depletion treatment before administering the immune tolerance induction composition or immune tolerance inducer, and more preferably both radiation and T-cell depletion treatment. Combining the immune tolerance induction composition or immune tolerance inducer with these immune system suppression treatments can efficiently induce immune tolerance to the donor-derived graft in the recipient, thereby improving the survival rate of the donor-derived graft in the recipient. It also makes it possible to avoid or reduce the administration of immunosuppressants to the recipient.
[0056] The radiation irradiation and T cell depletion treatment can be performed once or multiple times at a desired timing for induction of tolerance, either immediately before transplantation if it is desired to induce immune tolerance before transplantation, or at a desired timing for induction of tolerance if it is desired to induce immune tolerance after transplantation, i.e., to induce delayed tolerance induction. There is no particular limitation on the order of radiation irradiation and T cell depletion treatment, but it is preferable to perform the T cell depletion treatment prior to radiation irradiation.
[0057] The present disclosure provides a method for inducing immune tolerance in a mammalian individual, comprising administering an effective amount of pluripotent stem cells capable of forming teratomas, or teratomas derived from the pluripotent stem cells, to the mammalian individual in whom immune tolerance is desired.
[0058] The present disclosure also provides a method for improving the engraftment rate of a donor-derived transplant in a recipient, comprising administering (e.g., subcutaneously or intradermally) to the recipient an effective amount of teratoma-forming pluripotent stem cells or teratomas derived from the pluripotent stem cells, and transplanting a donor-derived transplant into the recipient. In such a method, the pluripotent stem cells are preferably derived from the donor or from a mammalian individual of the same species as the recipient and the donor, but different from both, and the recipient is preferably MHC-compatible with the donor. The administration of the pluripotent stem cells or teratomas and the transplantation of the donor-derived transplant may be performed simultaneously or at an interval. The administration of the pluripotent stem cells or teratomas and the transplantation of the donor-derived transplant may be performed within one day, for example, within 12 hours, 6 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, 15 minutes, 10 minutes, or 5 minutes. In addition, after administration of the pluripotent stem cells or teratoma, the donor-derived transplant can be transplanted at an interval of more than one day, for example, 3 days or more, 5 days or more, 7 days or more, 10 days or more, 20 days or more, 30 days or more, or 40 days or more.
[0059] Furthermore, the present disclosure provides a method for treating an autoimmune disease, comprising administering an effective amount of pluripotent stem cells capable of forming teratomas, or teratomas derived from the pluripotent stem cells, to a mammalian individual having the autoimmune disease.
[0060] In addition, the present disclosure provides a medical transplant kit comprising an effective amount of pluripotent stem cells capable of teratoma formation or teratomas derived from the pluripotent stem cells, and a donor-derived transplant. Such a kit can be suitably used in the above-mentioned method for improving the engraftment rate of a donor-derived transplant.
[0061] The present disclosure provides use of pluripotent stem cells capable of teratoma formation, or teratomas derived from said pluripotent stem cells, for the manufacture of a composition for inducing immune tolerance, particularly a pharmaceutical composition for inducing immune tolerance.The present disclosure provides use of pluripotent stem cells capable of teratoma formation, or teratomas derived from said pluripotent stem cells, for inducing immune tolerance.The present disclosure provides use of pluripotent stem cells capable of teratoma formation, or teratomas derived from said pluripotent stem cells, for transplantation medicine, particularly for improving the engraftment rate of donor-derived transplants in recipients in transplantation medicine.The present disclosure provides use of pluripotent stem cells capable of teratoma formation, or teratomas derived from said pluripotent stem cells, for the treatment or prevention of autoimmune diseases or allergic diseases.
[0062] The explanations of terms and preferred embodiments in each method, kit and use of the present disclosure are as explained in the context of the immune tolerance induction composition and immune tolerance induction agent.
[0063] The present invention will be specifically explained below by showing examples. However, these examples are intended to aid in understanding the present invention and are not intended to limit the technical scope of the present invention.
[0064] Materials and Methods. (1) Mice. C57BL / 6J (B6, MHC haplotype H-2b / b), CBA / N (MHC haplotype H-2k / k), 129X1 / SvJ Jms Slc (129, MHC haplotype H-2b / b), C3H / He (C3H, MHC haplotype H-2k / k), and BALB / c (MHC haplotype H-2d / d) mice were purchased from Japan SLC Co., Ltd. C3129F1 (MHC haplotype H-2k / b) mice were obtained by mating C3H females with 129 males. B6C3F1 (MHC haplotype H-2b / k) mice were obtained by mating B6 females with C3H males. All transplantation experiments were performed in accordance with the Hokkaido University Animal Experimentation Regulations. Regarding the MHC genotype notation, H-2b / b indicates homozygous for mouse MHC H2 haplotype b, H-2d / d indicates homozygous for H2 haplotype d, H-2k / k indicates homozygous for H2 haplotype k, and H-2k / b and H-2b / k indicate heterozygous for H2 haplotypes k and b.
[0065] (2) iPS cells. Fibroblasts were isolated from the ear skin tissue of adult B6, CBA / N, and 129 mice according to standard procedures. Four factors, Oct4, Sox2, Klf4, and c-Myc, were transduced into the fibroblasts using retroviral vectors to establish iPS cells derived from B6, CBA / N, and 129 mice (Takahashi et al., Cell, 2006, Vol. 126, pp. 663-676. DOI 10.1016 / j.cell.2006.07.024).
[0066] Mouse iPS cells were maintained on laminin-coated culture dishes in advanced DMEM / F-12 (1:1 mixture, Thermo, Sigma) supplemented with 0.5x Neuro Brew-21 (Miltenyi), 0.5x N2 supplement (Wako), 10 U / ml penicillin, 100 μg / ml streptomycin, 0.1 mM 2-mercaptoethanol (Nacalai), 0.03% L-glutamine (Gibco), 3 μM CHIR99021 (Adooq), 1 μM PD0325901 (Tocris), and recombinant human leukemia inhibitory factor (HREF) (in-house).
[0067] iPS cells were passaged as follows. The culture supernatant was removed from the culture medium grown in maintenance medium. The remaining culture medium was washed with PBS, and 1000 μl of trypsin (0.5 g / L trypsin / 0.53 mmol / L EDTA solution, Nacalai Tesque) was added and the cells were placed in an incubator. After 5 minutes, 5 ml of maintenance medium was added to neutralize the trypsin. The cells were sprayed with medium to form a single-cell suspension, which was then passed through a 40 μm filter into a tube and centrifuged at 1500 rpm at 4°C for 5 minutes. After centrifugation, the supernatant was removed and the cells were resuspended in maintenance medium. The cell concentration of the suspension was measured, and the required number of cells were seeded onto a laminin-coated dish and cultured again in maintenance medium.
[0068] (3) ES cells. Adult CBA / N mice were mated with the same strain, and blastocysts were obtained from the uterus 3.5 days after mating. Inner cell mass-like cell clusters were scraped from the hatched blastocysts and seeded on laminin-coated dishes for culture. SSEA1-positive cells, a pluripotent stem cell marker, were isolated and their teratoma formation ability was confirmed by a teratoma formation assay in nude mice (Marta Vila-Cejudo et al., J. Vis. Exp., 2017, 20;(126):56171. DOI: doi:10.3791 / 56171). ES cells were passaged in the same manner as iPS cells. The same culture medium (maintenance medium) was also used.
[0069] All pluripotent stem cells (iPS cells, ES cells) used in this example were confirmed to express the undifferentiated marker SSEA1. Furthermore, the pluripotent stem cells were transplanted into nude mice (BALB / c nu / nu), and the formed teratomas were collected and confirmed to have differentiated into the three germ layers.
[0070] (4) Generation of luciferase-expressing iPS cells. As described in Kamatani, T. et al. (Inflammation and Regeneration, (2022) 42:4. DOI 10.1186 / s41232-021-00190-7), fibroblasts were isolated from CBA / N mouse fetuses according to standard procedures. Four factors, Oct4, Sox2, Klf4, and c-Myc, were transfected into iPS cells using retroviral vectors. The luciferase gene was then introduced into the iPS cells using a lentiviral vector (pHIV-Luc-ZsGreen (Addgene)). Luciferase-expressing CBA / N mouse-derived iPS cells (Luc-CBA-iPS) were then generated.
[0071] (5) Subcutaneous inoculation of pluripotent stem cells. Recipient mice were anesthetized by intraperitoneal injection of a mixture of medetomidine (Domitor Nippon Zenyaku Kogyo Co., Ltd.), midazolam (midazolam injection, TEVA, Takeda Pharmaceutical Co., Ltd.), and butorphanol (Vetorphale, Meiji Seika). 2.5 × 10 6 iPS cells or ES cells were suspended in 50 μL of Matrigel and inoculated subcutaneously into recipient mice. Alternatively, the same volume of saline was suspended in 50 μL of Matrigel instead of the iPS cells or ES cells, and this was inoculated subcutaneously into recipient mice as an untreated control.
[0072] (6) Skin Graft Transplantation Recipient mice were anesthetized by intraperitoneal injection of a mixture of medetomidine, midazolam, and butorphanol. A circular excision of dorsal skin was performed to form a graft bed, and a piece of ear skin from a donor mouse was grafted onto it. The grafted skin was protected for 7 days after skin grafting, and the size of the grafted skin was measured over time. The rejection date was the day on which the grafted skin regressed to less than 30% of its size (longest diameter) on the day of grafting, and the period from the grafting date to the rejection date was the survival period of the grafted skin. The graft survival rate (overall survival) was calculated using the formula: (total number of grafted skin pieces - number of rejected skin pieces) / total number of grafted skin pieces × 100.
[0073] (7) In vivo imaging. The survival of transplanted cells in mice subcutaneously inoculated with Luc-CBA-iPS cells was monitored using IVIS Spectrum Imaging Systems (Spectrum-FL-TKHD; Caliper Life Sciences Ltd.). D-luciferin (Cayman) was administered intraperitoneally to mice at a dose of 120 mg / kg body weight. 20 minutes after administration, photons emitted from luciferase-expressing cells were collected with an integration time of 20 seconds, and the maximum number of photons per second (photon / second) was quantified.
[0074] (8) Statistical Analysis Statistical analysis was performed using JMP 16 (SAS Institute Inc.) unless otherwise noted. The significance level in this study was set at 5%, and a p-value below 5% was considered statistically significant. In each figure, a single asterisk (*) was added for p<0.05, and two asterisks (**) for p<0.01.
[0075] Example 1. iPS cell engraftment in syngenic and allogeneic recipients. Luc-CBA-iPS cells were subcutaneously inoculated into recipient mice (CBA / N, B6C3F1, BALB / c) (n = 5), and cell engraftment was analyzed by in vivo imaging. Ten days after iPS cell inoculation, teratomas were confirmed at the inoculation site in all CBA / N and B6C3F1 mice by visual and tactile observation.
[0076] For the transplanted Luc-CBA-iPS (H-2k / k), CBA / N mice (H-2k / k) correspond to syngenic recipients, B6C3F1 mice (H-2b / k) correspond to MHC-half-matched but minor-mismatched allogeneic recipients, and BALB / c mice (H-2d / d) correspond to MHC-mismatched and minor-mismatched allogeneic recipients. Therefore, Luc-CBA-iPS transplants into CBA / N and B6C3F1 mice are MHC-compatible, whereas Luc-CBA-iPS transplants into BALB / c mice are MHC-mismatched.
[0077] Figure 1 shows the time course of luciferin luminescence from the Luc-CBA-iPS cell inoculation site in the recipient mice. Strong luminescence was detected in the syngenic CBA / N mice 20 days after inoculation. Among the allogeneic recipients, luminescence was detected in the MHC half-matched B6C3F1 mice 30 days after inoculation, although weaker than in the CBA / N mice. Only faint luminescence was detected in the MHC-mismatched BALB / c mice 30 days after inoculation. These results confirmed that the transplanted iPS cells engrafted in the syngenic mice, engrafted weakly in the MHC half-matched minor-mismatched allogeneic mice, and did not engraft in the MHC-mismatched minor-mismatched allogeneic mice.
[0078] In addition to the combinations of iPS cells and recipient mice shown in Example 1, CBA / N-iPS, C57BL / 6 mouse-derived iPS cells (C57BL / 6-iPS), 129X1 mouse-derived iPS cells (129X1-iPS), and CBA / N mouse-derived ES cells (CBA-ES) were subcutaneously inoculated into C3129F1 mice and B6C3F1 mice, and cell engraftment and tumor formation were evaluated using the same method as in Example 1. The combinations of iPS cells and recipient mice in which engraftment and tumor formation of transplanted cells were confirmed are shown below.
[0079] Example 2. Teratoma formation by iPS cell transplantation. CBA / N mouse-derived iPS cells (CBA-iPS) were subcutaneously inoculated into B6C3F1 mice. More than 60 days after inoculation, tumors formed at the inoculation site were harvested. Formalin-fixed, paraffin-embedded sections of the tumors were prepared and stained with hematoxylin and eosin for pathological analysis. Tri-germline structures (ectodermal keratin pearl, mesodermal striated muscle, and endodermal ciliated epithelium) were observed within the tumors (Figure 2), confirming that the tumors formed were teratomas.
[0080] Example 3. Induction of immune tolerance by iPS cell transplantation (skin transplantation) CBA-iPS cells were subcutaneously inoculated into B6C3F1 mice, and 40 days after inoculation, skin fragments from donor mice (B6C3F1, CBA / N, BALB / c) were transplanted (CBA-iPS transplants (n = 4, B6C3F1; n = 4, CBA / N; n = 4, BALB / c), untreated (n = 10, B6C3F1; n = 10, CBA / N; n = 10, BALB / c)). Ten days after iPS cell inoculation, teratomas were confirmed to have formed at the inoculation site both visually and tactilely (by hand) in all mice subcutaneously inoculated with iPS cells.
[0081] The recipient B6C3F1 mice (H-2b / k) are allogeneic recipients that are half-MHC-matched and minor-mismatched to the transplanted CBA-iPS cells (H-2k / k). Therefore, transplantation of CBA-iPS cells into B6C3F1 mice is MHC-compatible.
[0082] The recipient B6C3F1 mice (H-2b / k) correspond to syngenic recipients for the B6C3F1 skin fragments (H-2b / k), to allogeneic recipients with partial MHC match and minor mismatch for the CBA / N skin fragments (H-2k / k), and to allogeneic recipients with MHC mismatch and minor mismatch for the BALB / c skin fragments (H-2d / d).
[0083] The survival time of the grafted skin is shown in Figure 3. B6C3F1 skin fragments completely engrafted in both the CBA-iPS transplant group and the untreated control group (administered saline). CBA / N skin fragments were completely rejected approximately 40 days after skin grafting in the untreated control group, but complete survival was confirmed in the CBA-iPS transplant group. BALB / c skin fragments were completely rejected within 20 days after skin grafting in both the CBA-iPS transplant group and the untreated control group. These results confirmed that donor-specific immune tolerance was induced in MHC-mismatched allogeneic recipients by transplantation of donor-derived iPS cells.
[0084] Example 4. Induction of immune tolerance by ES cell transplantation (skin transplantation) CBA-ES cells were subcutaneously inoculated into B6C3F1 mice, and 40 days after inoculation, skin fragments from donor mice (B6C3F1, BALB / c, 129X1, CBA / N) were transplanted (n = 3, B6C3F1; n = 3, BALB / c; n = 3, 129X1; n = 3, CBA / N). Ten days after ES cell inoculation, teratomas were confirmed to have formed at the inoculation site by both visual and tactile observation (by hand) in all mice subcutaneously inoculated with ES cells.
[0085] The recipient B6C3F1 mice (H-2b / k) are allogeneic recipients with half-MHC match and minor mismatch for the transplanted CBA-ES (H-2k / k). Therefore, transplantation of CBA-ES into B6C3F1 mice is MHC compatible.
[0086] Furthermore, the recipient B6C3F1 mice (H-2b / k) correspond to syngenic recipients for the B6C3F1 skin fragments (H-2b / k), to allogeneic recipients with partial MHC match and minor mismatch for the CBA / N skin fragments (H-2k / k) and 129X1 skin fragments (H-2b / b), and to allogeneic recipients with MHC mismatch and minor mismatch for the BALB / c skin fragments (H-2d / d).
[0087] The survival period of skin grafts in recipient mice subcutaneously inoculated with CBA-ES is shown in Figure 4. B6C3F1 and CBA / N skin grafts completely survived, whereas 129X1 and BALB / c skin grafts were completely rejected by 30 days after skin grafting. These results confirmed that donor-derived ES cell transplantation induces donor-specific immune tolerance in MHC-mismatched minor-mismatched allogeneic recipients.
[0088] CBA / N-iPS, C57BL / 6-iPS, and 129X1-iPS cells were subcutaneously inoculated into C3129F1 and B6C3F1 mice, respectively, using the same methods as in Examples 3 and 4. Cell engraftment and tumor formation were evaluated using the same combinations as those shown in Table 1. Teratomas were formed at the inoculation site 10 days after iPS cell inoculation, and the survival period of grafted skin was extended. This confirmed the induction of donor-specific immune tolerance in MHC-mismatched minor-mismatched allogeneic recipients.
[0089] Example 5. Effect of iPS cell transplantation timing on immune tolerance induction (skin transplantation). CBA-iPS cells were subcutaneously inoculated into B6C3F1 mice, and skin fragments from donor mice (B6C3F1, CBA / N, BALB / c) were transplanted on the same day as inoculation (specifically, within 4 hours after inoculation), 10 days, 20 days, 30 days, and 40 days after inoculation (day 10 (n = 4, B6C3F1; n = 5, CBA / N; n = 5, BALB / c), day 20 (n = 5, B6C3F1; n = 5, CBA / N; n = 5, BALB / c), day 30 (n = 5, B6C3F1; n = 5, CBA / N; n = 5, BALB / c), and day 40 (n = 11, B6C3F1; n = 13, CBA / N; n = 14, BALB / c). In all mice subcutaneously inoculated with iPS cells, the formation of teratomas at the inoculation site was confirmed visually and tactilely (by touching with the hands) 10 days after iPS cell inoculation.
[0090] The survival period of the grafted skin fragments is shown in Figures 5 and 6. When CBA / N skin fragments were grafted on the same day as CBA-iPS inoculation, survival was comparable to that of untreated controls (Figures 5A and 5B). However, when CBA / N skin fragments were grafted 10 days or more after CBA-iPS inoculation, the survival period increased with the time between CBA-iPS inoculation and skin grafting (Figures 5C and 6A-C). These results confirmed that at least 10 days, and preferably 20 days, are required for iPS cell transplantation to form teratomas and induce immune tolerance.
[0091] Example 6. Effect of teratoma resection on immune tolerance induction. CBA-iPS cells were subcutaneously inoculated into B6C3F1 mice. Ten days after iPS cell inoculation, teratoma formation at the inoculation site was confirmed visually and tactilely (by hand). Twenty days after inoculation, teratomas were excised from half of the mice, and skin fragments from donor mice (B6C3F1, CBA / N, BALB / c) were transplanted 40 days after inoculation (n = 5, B6C3F1; n = 5, CBA / N; n = 5, BALB / c). In addition, skin fragments from donor mice (B6C3F1, CBA / N, BALB / c) were transplanted into the remaining half of the mice 40 days after inoculation (n = 4, B6C3F1; n = 4, CBA / N; n = 4, BALB / c), and the teratomas were excised 20 days after skin transplantation.
[0092] The survival period of the grafted skin is shown in Figure 7. When the teratoma was excised 20 days before CBA / N skin grafting, the inoculated CBA-iPS cells did not extend the survival period (Figure 7A). When the teratoma was excised 20 days after CBA / N skin grafting, the inoculated CBA-iPS cells extended the survival period (Figure 7B). However, the extension was shorter than when the teratoma was not excised (Figures 3 and 6C). These results confirmed that the presence of teratomas formed from transplanted iPS cells is necessary for the induction of immune tolerance and indicated that teratoma maintenance is important for effective immune tolerance induction.
[0093] Example 7: Tracking of iPS cell-derived cells Luc-CBA-iPS cells were inoculated subcutaneously into B6C3F1 mice. 200 days after inoculation, the formed teratomas, spleens, teratoma-draining lymph nodes (dLNs), and teratoma-distant lymph nodes (non-dLNs) were harvested and analyzed for the presence of Luc-CBA-iPS cell-derived cells by in vivo imaging.
[0094] The amount of luciferin luminescence from each organ is shown in Figure 8. Strong luminescence was detected in the teratoma and weak luminescence was detected in the draining lymph nodes of the teratoma, but no luminescence was detected in distant lymph nodes. These results suggest that the presence of cells derived from transplanted iPS cells was limited to the draining lymph nodes, and that blood chimeras were likely not formed. They also suggest that blood chimera formation is unlikely to be involved in the mechanism of immune tolerance induction by iPS cell transplantation.
[0095] Example 8 Cell Surface Antigen Analysis of iPS Cells and Teratomas CBA-iPS cells were subcutaneously inoculated into B6C3F1 mice, and 40 days after inoculation, the formed teratomas were collected. TM Single-cell suspensions prepared using Dri Tumor and Tissue Dissociation Reagent (BD Biosciences) and single-cell suspensions of CBA-iPS cells were subjected to flow cytometry. Flow cytometry was performed using a BD FACSCelesta (Becton Dickinson) with Flowjo software (Tree Star). Live and dead cells were distinguished by forward scatter, side scatter, and 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) incorporation. The fluorochrome-conjugated monoclonal antibodies used are listed in Table 2. Isotype control antibodies or Fluorescence minus one (FMO) were used as controls.
[0096] The percentage of CD24-positive cells in the CD45-negative live cell population was calculated for single-cell suspensions prepared from teratomas and CBA-iPS cells. The flow cytometry analysis results are shown in Figure 9. CD24 expression was confirmed in both CBA-iPS cells and teratoma cells formed from CBA-iPS cells.
[0097] Example 9. Effect of Cd24a knockout in iPS cells on immune tolerance induction. CD24 CRISPR Plasmids mouse (SantaCruz) incorporating guide RNA for knocking out the mouse Cd24a gene was introduced into CBA-iPS cells according to the manufacturer's protocol, and CBA-iPS cells in which the Cd24a gene was knocked out (CD24 ko We generated CBA-iPS cells.
[0098] CBA-iPS or CD24 ko CBA-iPS cells were subcutaneously inoculated into B6C3F1 mice, and 40 days after inoculation, skin fragments from donor mice (B6C3F1, BALB / c, CBA / N) were transplanted (n = 8, B6C3F1; n = 8, CBA / N; n = 8, BALB / c). Ten days after inoculation, teratomas were confirmed at the inoculation site in all mice subcutaneously inoculated with iPS cells, both visually and tactilely.
[0099] The survival period of the grafted skin pieces is shown in Figure 10. In this experiment, the CBA / N skin pieces survived with a 75% probability when CBA-iPS cells were subcutaneously inoculated, whereas the CD24 ko When CBA-iPS cells were subcutaneously inoculated, the engraftment rate was only 50%. ko In mice subcutaneously inoculated with CBA-iPS cells, the teratomas disappeared in those that rejected the CBA / N skin fragments at the time of skin fragment rejection, suggesting that CD24 contributes to the induction of immune tolerance by iPS cell transplantation.
[0100] Example 10. Analysis of erythropoietin (EPO) expression in iPS cells and teratomas. CBA-iPS cells were subcutaneously inoculated into B6C3F1 mice, and teratomas formed 20 days after inoculation were harvested. Teratomas, ovaries, and kidneys were harvested 40 days after inoculation. The ovaries and kidneys are known to produce erythropoietin, and were used as positive controls in this example.
[0101] RNA was extracted from CBA-iPS cells, ovaries, and teratomas using Tripure Isolation Reagent (Roche Life Science). cDNA was synthesized using ReverTra Ace qPCR RT Master Mix (TOYOBO). RT-PCR was performed using the KAPA SYBR Fast qPCR Kit with the following primers: Mouse Epo forward primer 5'-TCGTGACATTTTCTGCCTCC-3' (SEQ ID NO: 1) reverse primer 5'-TCCCACCCTGCTGCTTTTAC-3' (SEQ ID NO: 2); Mouse Gapdh forward primer 5'-TCAAGTGGGGCGATGCTGGC-3' (SEQ ID NO: 3) reverse primer 5'-TTGCTGATGATCTTGAGGCT-3' (SEQ ID NO: 4). Formalin-fixed, paraffin-embedded sections of kidneys and teratomas were prepared and immunostained with an anti-EPO antibody (6E5, Sigma-Aldrich).
[0102] The expression level of the erythropoietin gene is shown in Figure 11, and the immunostaining image is shown in Figure 12. It was confirmed that teratomas, like the ovaries and kidneys, produce erythropoietin.
[0103] Example 11. Effect of Erythropoietin on Immune Tolerance Induction Skin fragments from CBA / N mice were transplanted onto B6C3F1 mice (n = 3, B6C3F1; n = 3, CBA / N; n = 3, BALB / c). B6C3F1 mice were intraperitoneally administered 5000 U / kg body weight of erythropoietin (Espoo Injection 750, Kyowa Kirin) on the day before (Day -1), the same day (Day 0), and the day after (Day 1) of skin transplantation. Subsequently, 1000 U / kg body weight of erythropoietin was intraperitoneally administered three times a week. Mice intraperitoneally administered with the same volume of saline instead of erythropoietin served as controls.
[0104] The survival period of the grafted skin is shown in Figure 13. Administration of erythropoietin extended the survival period of the CBA / N skin graft. This result suggests that erythropoietin contributes to immune regulation in MHC-mismatched minor-mismatched allogeneic recipients.
[0105] Example 12. Induction of immune tolerance by iPS cell transplantation (autoimmune disease) The induction of immune tolerance by iPS cell transplantation was evaluated using C3H / lpr mice, an autoimmune disease model. C3H / lpr mice are known to spontaneously develop lymphadenopathy and produce autoantibodies such as anti-dsDNA antibodies.
[0106] Five-week-old male C3H / lpr mice (Japan SLC Co., Ltd.) were anesthetized by intraperitoneal injection of a mixture of medetomidine, midazolam, and butorphanol. 2.5 × 10 6 CBA-iPS cells were subcutaneously inoculated into C3H / lpr mice (n = 4). C3H / lpr mice were also subcutaneously inoculated with the same volume of saline suspended in 50 μL of Matrigel instead of CBA-iPS cells and served as untreated controls (n = 5). Ten days after iPS cell inoculation, teratomas were confirmed at the inoculation site by visual and tactile inspection. Seven weeks after CBA-iPS cell inoculation, blood samples were collected, and anti-dsDNA IgG in the serum was measured using the Lebis® Anti-dsDNA Mouse ELISA Kit (Fujifilm Wako Shibayagi Co., Ltd.). Ten weeks after CBA-iPS cell inoculation, lymph nodes draining the teratomas were harvested and weighed.
[0107] The C3H / lpr mice (H-2k / k) are MHC-matched but minor-mismatched allogeneic recipients of the transplanted CBA-iPS cells (H-2k / k). Therefore, transplantation of CBA-iPS cells into C3H / lpr mice is MHC-compatible.
[0108] Anti-dsDNA IgG and lymph node weight are shown in Figure 14. For comparison, data from male C3H mice of the same age are also shown in Figure 14. Both anti-dsDNA IgG and lymph node weight were high in untreated controls, but were reduced in C3H / lpr mice inoculated with CBA-iPS cells. These results confirmed that iPS cell transplantation can induce immune tolerance in autoimmune diseases. Furthermore, C3H / lpr mice inoculated with CBA-iPS cells did not lose weight, and no abnormalities in appearance or behavior were observed.
[0109] Example 13. Single-cell RNA analysis of time-dependent changes in immune cells infiltrating into teratomas. The immune cells infiltrating into CBA-iPS-derived teratomas formed in B6C3F1 mice were compared over time using single-cell RNA analysis. CBA-iPS cells were subcutaneously inoculated into B6C3F1 mice. Teratomas were collected on the same day at 10 days (n=33), 20 days (n=20), and 40 days (n=20) after formation, and were grouped together for subsequent processing at each time point. Teratomas obtained from the three time points were then transfected with BD Horizon TMSingle-cell suspensions were prepared using Dri Tumor & Tissue Dissociation Reagent (BD Biosciences), and CD45+ cells were fractionated using a FACSAria II (BD Biosciences). Complementary DNA was generated and scRNA-seq libraries were prepared according to the 10x Genomics protocol for NextGEM Single Cell 3' Gene Expression v3.1 (CG000315 Rev C). Libraries were sequenced on an Illumina NovaSeq X system (Takara Bio Inc., Japan). Raw sequencing data were processed using Loupe Cell Browser (10x Genomics) and further processed using the R package Seurat (v4.0.1) to filter low-quality cells. Normalization, scaling, and variable gene selection were performed using the SCTransform function in Seurat, and principal component analysis (PCA) was performed on the resulting gene expression matrix. Cells were then assigned to 13 clusters using Uniform Manifold Approximation and Projection (UMAP). Cell types were annotated based on known cellular markers and differential gene expression analysis, and results were visualized using R (v4.0.1) and Seurat, ggplot2, dplyr, dittoSeq, and nebulosa.
[0110] Based on gene expression profiles, regulatory T cells (Tregs) infiltrating teratomas were classified into three clusters: Treg-1, Treg-2, and Treg-3 (Figure 15A). Treg-1 marker genes include trp53inp1, Lrig1, Zfp260, Itgae, and Myo3b; Treg-2 marker genes include Slamf8, Ifi205, Mgl2, Cd209a, and Htr7; and Treg-3 marker genes include Pbk, Pclaf, Cenph, Neil3, and Kif14 (Figure 15B). The Treg-1 marker genes, Lrig1 and Itgae, are known to be marker genes for Tregs with high immunosuppressive potential. Treg-1 cells also strongly expressed the known immunosuppressive factors Il10, Il2ra, Clta4, Entpd1, and Nt5e (Figure 15C).
[0111] When the abundance ratio of each Treg cluster in teratomas was compared at each time point, the proportion of Treg-1 among all Tregs tended to increase over time, suggesting a relationship between immune tolerance induction and Treg-1 (Figure 15D).
[0112] Example 14. Effect of regulatory T cells on immune tolerance induction. CBA-iPS cells were subcutaneously inoculated into B6C3F1 mice, and anti-CD25 antibody (clone: PC61) or isotype control Control IgG was administered intraperitoneally at 30 μg / mouse once every three days for 60 days from the day of inoculation. The CD25 antibody was used to remove Tregs. Ten days after iPS cell inoculation, teratomas were confirmed macroscopically and tactilely at the inoculation site in all mice. Forty days after iPS cell inoculation, skin fragments derived from CBA / N mice were transplanted.
[0113] The survival period of the grafted skin is shown in Figure 16. The survival rate of CBA / N skin grafts was significantly reduced by administration of anti-CD25 antibody compared with that of control IgG, suggesting the contribution of Tregs to the induction of immune tolerance accompanied by teratoma formation.
[0114] Example 15. Induction of immune tolerance in the early stage after iPS cell transplantation (skin transplantation) The same experiment as in Example 5, in which iPS cells and skin fragments were transplanted on the same day, was repeated three times. Specifically, CBA-iPS cells were subcutaneously inoculated into B6C3F1 mice, and skin fragments derived from CBA / N mice were transplanted within 4 hours after inoculation. In all mice subcutaneously inoculated with iPS cells, the formation of teratomas at the inoculation site was confirmed visually and tactilely 10 days after iPS cell inoculation.
[0115] The survival period of the grafted skin fragments is shown in Figure 17. The test conducted in Example 5 is designated as Trial 1, and the additional tests conducted in this Example are designated as Trials 2 to 4. Unlike Trial 1, Trials 2 to 4 demonstrated long-term survival of the skin fragments even when iPS cells and skin fragments were transplanted on the same day. These results confirmed that immune tolerance is rapidly induced by transplanting iPS cells and skin fragments on the same day. Without being bound by theory, the immune tolerance observed in this Example at an early stage after iPS transplantation, unlike the immune tolerance observed in other Examples, does not require prior teratoma formation, suggesting the existence of a different mechanism of action.
[0116] That is, immune tolerance induction compositions and immune tolerance inducers containing pluripotent stem cells can induce immune tolerance without teratoma formation by transplanting pluripotent stem cells into a mammalian individual that is MHC-compatible with the pluripotent stem cells contained therein. This is presumably because immune tolerance can be acquired in an MHC-compatible mammalian individual by either (1) the transplanted pluripotent stem cells themselves, (2) any cells that have progressed in differentiation from the transplanted pluripotent stem cells into non-teratomas, or (3) cells that are in the process of differentiating from the transplanted pluripotent stem cells into teratomas.
Claims
1. A composition for inducing immune tolerance, comprising pluripotent stem cells having teratoma-forming ability, or a teratoma derived from the pluripotent stem cells.
2. The composition of claim 1, wherein the pluripotent stem cells express CD24.
3. The composition of claim 1, wherein the teratoma expresses CD24.
4. The composition according to claim 1, wherein the teratoma has the ability to produce erythropoietin.
5. The composition described in claim 1, wherein the teratoma has the ability to accumulate or infiltrate regulatory T cells.
6. The composition of claim 1, wherein the pluripotent stem cells are embryonic stem cells or induced pluripotent stem cells.
7. The composition described in claim 1 for use in a mammalian individual having MHC compatibility with pluripotent stem cells.
8. The composition according to claim 1 for use in a recipient receiving a transplant of donor-derived cells, tissue or organs.
9. The composition of claim 8, wherein the pluripotent stem cells are derived from a donor.
10. The composition of claim 8, wherein the recipient is MHC compatible with the donor.
11. A method for inducing immune tolerance in a mammalian individual, comprising administering to the mammalian individual in which immune tolerance is desired an effective amount of pluripotent stem cells having teratoma-forming ability, or a teratoma derived from the pluripotent stem cells.
12. A method for improving the survival rate of donor-derived cells, tissues or organs in a recipient, comprising administering to the recipient an effective amount of pluripotent stem cells having teratoma-forming ability, or a teratoma derived from the pluripotent stem cells, and transplanting the donor-derived cells, tissues or organs into the recipient.
13. A method for treating an autoimmune disease, comprising administering an effective amount of pluripotent stem cells having teratoma-forming ability, or a teratoma derived from said pluripotent stem cells, to a mammalian individual having the autoimmune disease.
Citation Information
Patent Citations
Method for generating induced pluripotent stem cells and progenitor cells from fibroblasts
JP2013507974A
Isolation of amniotic fluid-derived pluripotent stem cells and their use in the treatment or prevention of autoimmune diseases
JP2013532989A
Automated system for generating induced pluripotent stem cells or differentiated cells
JP2015502747A
Hematopoietic cells from human embryonic stem cells
JP2016187354A
Methods of modulating immunoregulatory effects of stem cells
JP2016504324A
